P4016Outcomes in vitamin K antagonist treated atrial fibrillation patients with stable international normalized ratios

Anders Nissen Bonde; Laila Stærk; Gunnar Gislason; Christian Torp‐Pedersen; Professor Gregory Lip; Jonas Bjerring Olesen

doi:10.1093/eurheartj/ehx504.p4016

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Letter2023

Antidiabetic drugs and hypoglycaemia risk in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants

Katarzyna Nabrdalik, Hanna Kwiendacz, Professor Gregory Lip

Article2021

Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants

Yi‐Hsin Chan, Tze‐Fan Chao, Hsin‐Fu Lee, Shao‐Wei Chen, Pei‐Ru Li, Jia‐Rou Liu, Lung‐Sheng Wu, Shang‐Hung Chang, Yung‐Hsin Yeh, Chi‐Tai Kuo, Lai‐Chu See, Professor Gregory Lip

Article2021

Time at home among nonvalvular atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants versus warfarin

Steven Deitelzweig, Allison Keshishian, A Kang, Aaron Jenkins, Nipun Atreja, Patricia Schuler, Jenny Jiang, K Lovett, Hüseyin Yüce, Professor Gregory Lip

Article2021

Time at home among nonvalvular atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: an ARISTOPHANES analysis

Steven Deitelzweig, Allison Keshishian, A Kang, Aaron Jenkins, Nipun Atreja, Patricia Schuler, Jenny Jiang, K Lovett, Hüseyin Yüce, Professor Gregory Lip

Article2019

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage

Peter Brønnum Nielsen, Flemming Skjøth, Mette Søgaard, Jette Nordstrøm Kjældgaard, Professor Gregory Lip, Torben Bjerregaard Larsen